Clinical Trial Update: Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) [Phase 3]

View source ↗

Summary

Phase 3 trial update on blinatumomab in Chinese adults with relapsed/refractory B-precursor acute lymphoblastic leukemia; results completed with efficacy and sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: Acute Lymphoblastic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2020-09-14